Effect of Cardiopulmonary Bypass on the Pharmacokinetics of Drugs
- 1 January 1982
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 7 (3) , 234-251
- https://doi.org/10.2165/00003088-198207030-00004
Abstract
The cardiopulmonary bypass apparatus must temporarily substitute for the cardiac and pulmonary function of the patient undergoing heart surgery. In order to meet the metabolic needs of the patient...Keywords
This publication has 77 references indexed in Scilit:
- Administration of heparin causes release of non-esterified fatty acids in human plasmaLife Sciences, 1980
- Clinical Pharmacokinetics of Digoxin 1980Clinical Pharmacokinetics, 1980
- Clinical Pharmacokinetics of PropranololClinical Pharmacokinetics, 1979
- Role of the Lung in Total Body Clearance of Circulating DrugsClinical Pharmacokinetics, 1979
- Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid GlycoproteinNew England Journal of Medicine, 1978
- Pharmacokinetics of cefamandole using a HPLC assayJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Clinical Pharmacokinetics of DigoxinClinical Pharmacokinetics, 1977
- Serum, Atrial, and Urinary Digoxin Levels During Cardiopulmonary Bypass in ChildrenCirculation, 1974
- Serum Digitalis and Arrhythmia in Patients Undergoing Cardiopulmonary BypassCirculation, 1973
- Relationship Between Alterations in Renal Hemodynamics During Cardiopulmonary Bypass and Postoperative Renal FunctionCirculation, 1966